Subjects should be screened within 14 days before receiving APL-2. Upon entry into the study, subjects will be assigned a screening number. Patients who meet all inclusion and exclusion criteria and are confirmed as eligible by the CRC will return to the clinic for randomization and treatment on visit 2 (Day 0). At this visit, subjects will be randomized in a 2:2:1:1 manner to receive APL 2 Monthly (AM), APL-2 Every-Other-Month (AEOM), Sham injection Monthly (SM) or Sham injection Every-Other-Month (SEOM), respectively.